Medical Insulin Delivery Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Insulin Delivery Devices
1.1 - About Medical Insulin Delivery Devices sector
Companies in the Medical Insulin Delivery Devices category design and manufacture hardware and software that administer insulin accurately and consistently for people with diabetes. Offerings span pumps, pens, patch devices, infusion consumables, and connected dosing tools that integrate with glucose data. The value proposition centers on safer dosing, improved glycemic control, and streamlined therapy management across clinical and home settings, making these vendors common strategic buyers in diabetes drug delivery.
Vendors typically offer tubed and tubeless insulin pumps, patch pumps, and smart insulin pens with dose tracking, paired with pen needles, infusion sets, and reservoirs. Many provide automated insulin delivery algorithms and bolus calculators integrated with CGM via Bluetooth, plus companion mobile apps and cloud portals for remote monitoring. Additional capabilities include clinician dashboards, device interoperability, patient onboarding and training programs, and reimbursement and supply management for consumables.
They serve health systems and hospitals, diabetes clinics and endocrinology practices, and DME distributors and pharmacies. Outcomes include measurable HbA1c reduction, fewer hypoglycemic events, higher therapy adherence, and lower total cost of care through reduced acute episodes and optimized consumable utilization. Buyers also gain better data visibility for care management, streamlined workflows for device provisioning, and improved patient satisfaction and retention in diabetes programs.
2. Buyers in the Medical Insulin Delivery Devices sector
2.1 Top strategic acquirers of Medical Insulin Delivery Devices companies
Tandem Diabetes Care
- Description: Provider of insulin delivery and diabetes technology solutions, manufacturing automated insulin delivery systems such as the Tandem Mobi and t:slim X2 pumps with Control-IQ hybrid closed-loop technology, and offering complementary diabetes education, pump training, software updates and benefit programs for effective blood-glucose management in multiple international markets.
- Key Products:
- Tandem Mobi system: Wearable, ultra-compact automated insulin delivery pump utilizing Control-IQ technology to continuously adjust basal insulin, providing personalized glucose control with minimal device footprint
- t: slim X2 insulin pump: Touchscreen insulin pump featuring Control-IQ hybrid closed-loop algorithm that automatically delivers and suspends insulin based on glucose sensor data to ease daily diabetes management
- t: connect Diabetes Management Application: Cloud-based app that syncs pump and glucose data, offering users and clinicians real-time dashboards and reports to monitor trends, adjust therapy, and improve outcomes
- t: simulator Insulin Pump Demo App: Mobile simulation app replicating the t:slim X2 pump interface, enabling prospective users and educators to practice programming and navigation without live insulin delivery.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Insulin Delivery Devices sector
M&A buyer group 1: Diabetes Devices
DarioHealth
- Type: N/A
- Employees: ●●●●●
- Description: Provider of data-driven digital health solutions for chronic condition management, offering an integrated platform of connected devices, mobile apps and analytics for diabetes, hypertension, weight, behavioral and musculoskeletal care, as well as employer and health-plan programs that improve outcomes and lower costs.
- Key Products:
- Diabetes Management Solution: Smartphone-connected digital therapeutic combining real-time glucose monitoring, personalized coaching, and evidence-based interventions to drive sustained behavior change and improved glycemic control
- Hypertension Management Solution: AI-driven program that pairs connected blood-pressure monitoring with adaptive software and coaching to help users track readings, receive feedback, and lower blood-pressure levels
- Cardiometabolic Suite for Employers: Multi-condition platform offered to employer populations, bundling diabetes, hypertension and related chronic-care programs to generate recurring outcomes-based revenue
- Multi-Condition Digital Therapeutics Platform: Core software infrastructure integrating life-science, behavioral-science and analytics capabilities to rapidly expand into additional chronic conditions and geographic markets.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Insulin Delivery Devices sector
3.1 - Buyout funds in the Medical Insulin Delivery Devices sector
2.2 - Strategic buyer groups for Medical Insulin Delivery Devices sector
4 - Top valuation comps for Medical Insulin Delivery Devices companies
4.2 - Public trading comparable groups for Medical Insulin Delivery Devices sector
Valuation benchmark group 1: Diabetes Care Device Companies
Medtronic
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of medical technology solutions including advanced devices and therapies for various medical conditions, focusing on cardiac care, neurological disorders, diabetes management, and surgical innovations to improve patient outcomes and enhance healthcare delivery.
- Key Products:
- Cardiac devices: Pacemakers and defibrillators for heart rhythm disorders
- Insulin pumps: Advanced systems for diabetes management
- Surgical innovations: Minimally invasive surgical tools and robotics
- Neurostimulation: Implants for pain management and neurological conditions
- Patient monitoring: Advanced monitoring systems for acute care.